NewsRoom Articles - Page 99 of 154 - PsychedelicNewsWire (PNW)

FridayMay 07, 2021 2:00 pm

How Psilocybin Testers Identify Award-Winning Magic Mushrooms

Last weekend, enthusiasts of plant medicine took part in the first-ever Psilocybin Cup. The event, which was organized by an incubation lab and consulting firm in Oakland, California, called Oakland Hyphae, had growers of magic mushrooms submit their mushrooms to the lab. This event comes after the City Council of Oakland decriminalized psychoactive plants and fungi, which include psilocybin mushrooms, in 2019. Researchers tested the samples that had been submitted for the cup by more than 50 cultivators in order to determine how much psilocin and psilocybin were in each mushroom. The two ingredients are hallucinogenic compounds found in psilocybin…

FridayMay 07, 2021 1:46 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Investigates Alleviating Neurological Disorders with Psychedelics

Tryp Therapeutics is a pharmaceutical developer working to produce novel bioscience solutions, including a synthetic psychedelic drug candidate for treating some chronic pain and eating disorders Tryp CEO Greg McKee appeared on the Entrepreneur Magazine podcast “Action and Ambition” earlier this month to discuss lessons learned on his road to success and to highlight the company’s purpose in developing treatments for helping people be more whole Psychedelic drug therapies have been developing a growing fanbase, highlighted by California state Sen. Scott Wiener’s legislation this year seeking to decriminalize hallucinogenics McKee noted that many military personnel are using psychedelics in an…

ThursdayMay 06, 2021 2:00 pm

Study Finds Complex Relationship Between Creativity, Psilocybin

A new study has discovered that individuals under the influence of psilocybin tend to have more original and profound thoughts. However, cognitive tests on creative ability conducted have shown that they score lower in the short term, with findings indicating that psilocybin, which is the active ingredient in magic mushrooms, improves an individual’s creative ability in the long term. The research gathered proton magnetic resonance spectroscopy and functional magnetic resonance imaging data. which offered new insights into the basic neurobiological mechanisms linked to creativity. Maastricht University PhD candidate Natasha Mason, who also happens to be the lead researcher of the…

WednesdayMay 05, 2021 2:00 pm

Psychedelic Experience Not Necessary for Individuals to Benefit from Psilocybin’s Antidepressant Effects

Researchers from the University of Maryland School of Medicine have demonstrated that psilocybin can act an as antidepressant even if a psychedelic experience doesn’t occur. Psilocybin is the active ingredient found in magic mushrooms. The findings propose that psychedelic substances work in different ways within the brain. It is therefore possible to confer the drug’s antidepressant benefits without the need of therapy sessions. A variety of psilocybin that has less of or no psychedelic effect could help lower the cost of therapy and ease restrictions on individuals who receive therapy, which would make the beneficial effects of psilocybin better available…

WednesdayMay 05, 2021 12:04 pm

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Signs Drug-Development Agreement, One Step Closer to Effective Psychiatric Disorder Treatment

Agreement calls for Cybin, Catalent to work together to develop novel therapy for treatment-resistant psychiatric disorders Cybin looking to identify fast-acting, shorter-duration formulations of CYB003 Delivering CYB003 through Catalent ODT could provide significant benefits Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has inked a drug-development agreement with Catalent Inc. (NYSE: CTLT), a leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products (https://ibn.fm/nQdpg). The agreement, which is scheduled to start this month, calls for the two companies to work together to potentially…

WednesdayMay 05, 2021 8:10 am

Marigold PR Announces Agenda and Expert-Driven Lineup for Second Annual Womxn, Wellness, and Cannabis Conference

Award-winning cannabis marketing and PR firm, Marigold PR, today announced the agenda for its second annual Womxn, Wellness and Cannabis Conference (WWC Conference) on May 26-27, 2021. Hosted in celebration of the feminine cannabis and psychedelic experience, the largest free event of its kind provides a unique opportunity to network with industry trailblazers, in an inclusive, fun and educational online environment. In association with Platinum Partner Lift & Co. Expo, North America’s largest cannabis industry conference and tradeshow, WWC Conference will feature two full days of engaging panel discussions, keynotes and live Q&As, with day one committed to cannabis and…

TuesdayMay 04, 2021 3:00 pm

Ancient Spiritual Psychedelic Practices May Aid the Legalization Movement

The legalization of marijuana is often considered to be a model for psychedelics. Thus far, marijuana has been legalized for both medical and recreational use in various nations across the globe and in numerous states in the United States. From the above, one can deduce that there are two primary ways to end the ban on psychedelics: decriminalization or medicalization. However, while those two options are effective, they conceal another way of using psychedelics: obtaining legal sanction for the religious or spiritual use of psychedelics that are considered sacred tools for holy rituals in various traditions. Here, we are referring…

TuesdayMay 04, 2021 2:24 pm

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Inks Distribution Agreement for Rapid COVID-19 Test Kits; Expands Commercial Leadership Team in Anticipation of Strong, Sustainable Sales

XPhyto Therapeutics Corp. recently announced it has entered into a distribution, storage and logistics agreement with a German distributor with an established network throughout Germany Germany holds promise due to regulations requiring mandatory weekly testing for its citizens; this has the possibility of ramping up sales Anticipating the increase in sales and distribution, XPhyto expanded its commercial leadership team by bringing on board Mr. Wolfgang Probst and Mr. Manfred Buchberger Mr. Probst will be the company’s Chief Operations Officer (“COO”), while Mr. Buchberger will be the Head of Corporate Development at wholly owned subsidiary XP Diagnostics GmbH The approvals XPhyto…

TuesdayMay 04, 2021 11:44 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Leading Charge in Developing Psychedelic Medicines for Treating Rare Eating Disorders

Pharmaceutical developer Tryp Therapeutics is targeting orphan disorders with novel medicinal solutions The company’s initial candidates seeking regulatory approval are a psilocybin compound for treating fibromyalgia, eating disorders and chronic pain conditions, as well as a tumor-inhibiting drug for treating soft tissue sarcomas Tryp has partnered with the University of Florida to conduct a Phase 2a clinical trial for eating disorders using Tryp's psilocybin product Following a year in which a global pandemic led to heightened concerns about individuals’ mental well-being while navigating the health emergency’s effects on society (https://ibn.fm/YGqDb), proponents of psychedelic medicine development programs gained stronger allies in…

MondayMay 03, 2021 3:00 pm

Scientists Criticize Drug War at Psychedelics Event Hosted by Federal Health Agency

Last week, a federal health agency begun a speaker series that will be focused on reviewing the science behind psilocybin mushrooms and the therapeutic potential they possess. Experts who aired their views at the inaugural event claimed that federal drug regulations undermined the scientific community’s research objectives and weren’t in line with what the voters wanted. The event is being hosted by the National Cancer Institute, under the National Institutes of Health (“NIH”). The institute notes that it has some clinical trials looking into the use of psilocybin as a treatment of cancer-related depression, with others exploring the psychedelic’s potential…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000